Janssen’s plaque psoriasis treatment Tremfya was found to be superior to Novartis’ Cosentyx in treating adults with moderate-to-severe cases of the condition, according to findings of a late-stage study. More: Plaque psoriasis study claims Tremfya superior to Cosentyx Source: News
read moreA new study has shown that people who live in rural areas are less likely to survive cancer than those who live in cities. More: Rural patients less likely to survive cancer, study finds Source: News
read moreJohnson & Johnson’s Tremfya may have made its debut after key rivals, but it made waves Wednesday in the next-gen psoriasis field with Cosentyx-topping head-to-head data. So much so that rival Novartis felt the need to host its own Cosentyx-defending
read moreEngland’s pharma gatekeepers aren’t impressed by the cost-effectiveness numbers on Alnylam and Ionis’ new drugs to treat the rare disease hereditary transthyretin-mediated amyloidosis (ATTR). Neither one is cost-effective, NICE says, but both companies will be trying to change the agency’s
read moreCould a still-recovering company buying a distressed one create a better business? Bausch Health apparently thinks so when it comes to Synergy Pharma, as it’s agreed to pay $200 million for the now-bankrupt maker of Trulance. More: Bausch Health inks
read moreSince Pfizer’s Kansas plant received an FDA warning letter last year, the company has insisted it is making good progress on turning things around at the essential but troubled injectables facility. But the findings from the most recent inspection show
read more© 1994 - 2026 B.M. Pharmaceuticals